Articles By Ed Miseta

31. Tufts Finds Substantial Net Benefits To Using Decentralized Trials 7/28/2022

    For years, vendors have touted decentralized clinical trials (DCTs) as a solution to both the time and cost challenges. DCTs also promise to make trials more patient centric. Unfortunately, a demonstration of the actual benefits of DCTs, along with a quantifiable dollar amount, have been difficult to produce. Until now.

32. How To Become A Sponsor Of Choice For Your CRO Partners 7/26/2022

    Becoming a true sponsor of choice involves much more than simply saying the words. Drug discovery is a tough business and there are many parts that must seamlessly interact to get a product to regulatory approval.

33. Novartis Lights A Beacon Of Hope For Diversity And Inclusion 7/21/2022

    In June 2022 Novartis announced the expansion of its Beacon of Hope program. The program is a 10-year, multimillion dollar program being conducted in collaboration with 26 historically Black colleges, universities, medical schools, Thurgood Marshall College Fund (TMCF) and other key partners.

34. I Have Cancer, And I'm Thankful For The Life Science Industry 7/18/2022

    Your life can change in an instant. Mine changed in July 2021 when I was diagnosed with multiple myeloma. Here is why I am so thankful to pharma companies, patients, sites, and CROs.

35. Site Prices Are Skyrocketing – Here's Why & What You Can Do About It 7/13/2022

    Pricing at clinical trial sites has increased dramatically over the last two years. Site contracts are now a concern for all sponsor companies, and an even bigger concern for smaller CROs struggling with steadily rising study budgets.

36. CVS Health Wants To Be Your New Clinical Research Site 7/6/2022

    CVS has been a well-regarded and recognized healthcare brand that started as a pharmacy but has since migrated into a recognized and trusted healthcare company. Now CVS is hoping to expand the relationship it has with patients by moving closer into primary care and clinical trials.

37. Takeda Takes A Strategic Approach To TMF 6/21/2022

    Over the past five years, Takeda has been perfecting its all-in model for TMF, where both Takeda and its CRO partners collaborate in Takeda's eTMF. This enables transparency into TMF health across the partnership and drives more effective, proactive collaboration.

38. What Should You Look For In A CRO Partner? 6/16/2022

    In May 2022, ISR Reports released the 14^th edition of its Phase II/III CRO Benchmarking Report. The landscape for outsourcing clinical research changes every year, and the goal of the report is to help sponsor companies make educated decisions and to help CROs understand how they stack up against competitors when it comes to brand positioning and performance metrics.

39. SCRS Puts A Spotlight On Diversity 6/9/2022

    When asked about patient diversity in clinical trials, Diana Foster likes to reflect back to 2016. Foster, VP, strategy and special projects & diversity awareness program lead at the Society for Clinical Research Sites (SCRS), notes that was the year a group of individuals from approximately 40 organizations gathered in Washington D.C. to discuss diversity.

40. AstraZeneca's Oncology Goal: Separate Efficacy And Toxicity 6/6/2022

    Matthew Ellis, SVP of Early Oncology R&D for AstraZeneca, is helping lead the charge in what he calls the company's oncology revolution. Ellis deals with the complicated process of going from the discovery of a potential therapeutic target or mechanism to the discovery and development of potential medicines, the triage of those medicines, and working out the right risk-benefit profile so they can be administered to humans.